Impact of national valsartan recalls on Veterans’ outcomes
Background and Aims: Chemical impurities discovered in angiotensin receptor blocker (ARB) products in late 2018–2019 resulted in recalls of various products and has likely had downstream effects for patients and prescribers. The purpose of this study is to determine how the valsartan recall impacted...
Main Authors: | Paige L. Morizio, Sara R. Britnell, Andreina A. Ottman |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-06-01
|
Series: | Therapeutic Advances in Drug Safety |
Online Access: | https://doi.org/10.1177/20420986211016173 |
Similar Items
-
Economic outcomes associated with an investigational drug service within a Veterans Affairs health care system
by: Jamie N. Brown, et al.
Published: (2019-06-01) -
Valsartan, Losartan and Irbesartan use in the USA, UK, Canada and Denmark after the nitrosamine recalls: a descriptive cohort study
by: Anton Pottegård, et al.
Published: (2023-04-01) -
Sacubitril/Valsartan Initiation Among Veterans Who Are Renin‐Angiotensin‐Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction
by: April F. Mohanty, et al.
Published: (2021-10-01) -
Effect of valsartan on kidney outcomes in people with impaired glucose tolerance.
by: Currie, G, et al.
Published: (2017) -
Effects of the July 2018 worldwide valsartan recall and shortage on global trends in antihypertensive medication use: a time-series analysis in 83 countries
by: Jared W Magnani, et al.
Published: (2023-01-01)